Strontium sits just below calcium on the periodic table, and that chemical resemblance is both its appeal and its problem. The element slips into bone in place of calcium, but the swap does not make bone stronger. Instead, it inflates bone density readings on standard scans, may impair normal mineralization, and carries cardiovascular risks serious enough that European regulators moved to restrict the only prescription form ever approved. For people turning to over-the-counter strontium citrate supplements hoping to protect their skeleton, the picture is even murkier: there are no human trials proving those products work, and the density “gains” they appear to produce on a scan may be almost entirely an artifact of how strontium interacts with X-rays.
How Strontium Gets Into Bone
Your body handles strontium much the way it handles calcium, because the two elements are chemically similar. They share absorption pathways in the gut, and vitamin D promotes strontium uptake just as it does calcium uptake. Calcium actually inhibits strontium absorption, so taking the two together reduces how much strontium gets in.1Bone. The biological role of strontium Once absorbed, strontium travels to the skeleton and deposits in areas where new bone is actively forming. Research using fluorescence mapping has shown that only bone packets laid down during strontium treatment contain meaningful amounts of the element, with up to about one in twenty calcium atoms replaced by strontium in the mineral crystals.2Journal of Bone and Mineral Research. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment Animal studies largely agree, finding that most ingested strontium either sits on the crystal surface or lodges in the surrounding bone matrix rather than deeply substituting into the mineral lattice itself.3PubMed. The morphology and lattice structure of bone crystal after strontium treatment in goats
This partial replacement matters because strontium atoms are larger and heavier than calcium atoms. That physical difference is the root of the measurement problems discussed below, and it also means the mechanical properties of the crystal lattice are being altered, not simply reinforced.
The DEXA Scan Illusion
Dual-energy X-ray absorptiometry, the standard bone density scan, works by measuring how much X-ray energy bone absorbs. Strontium absorbs X-rays more strongly than calcium does, so when strontium replaces even a small fraction of calcium in bone, the scan reads a higher density than the bone actually has. This is not a subtle effect. Researchers have found that for every one percent of strontium incorporated into bone crystal, bone mineral density is overestimated by roughly ten percent.4Journal of Nutrition Health & Food Science. Change in Bone Mineral Density with Strontium Citrate: An Illusion or Reality The relationship between strontium content and BMD overestimation is direct and linear, meaning the more strontium present, the larger the error.5Journal of Clinical Densitometry. Influence of Strontium on Bone Mineral Density and Bone Mineral Content Measurements by Dual X-Ray Absorptiometry
This creates a practical trap. You start taking a strontium supplement, go back for a DEXA scan a year later, and the numbers look better. You and your doctor might celebrate what appears to be genuine improvement. But a meaningful chunk of that “improvement” is an artifact of heavier atoms sitting where lighter ones used to be, not new bone tissue being built. One analysis put it plainly: much of the bone density increase seen with strontium citrate is likely due to this atomic-weight effect rather than genuine skeletal strengthening.4Journal of Nutrition Health & Food Science. Change in Bone Mineral Density with Strontium Citrate: An Illusion or Reality Clinicians who are aware of strontium use can try to adjust for the overestimation, but standard DEXA software does not do this automatically.6PubMed. Effect of bone strontium on BMD measurements
Did Strontium Ranelate Actually Reduce Fractures?
Here is where the story gets genuinely complicated. Strontium ranelate, the prescription drug sold in Europe under the brand name Protelos, did reduce fractures in large clinical trials. In postmenopausal women with osteoporosis, treatment lowered the risk of new vertebral fractures by about 41% over three years compared with placebo, and reduced non-vertebral fractures by around 16%.7PubMed Central. Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy At one year, the vertebral fracture reduction was even steeper, reaching 49%.8PubMed Central. Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis
So if strontium ranelate prevented fractures, why say strontium is not good for bone? A few reasons. First, an unknown portion of the “improved” bone density in those trials was the DEXA artifact rather than real structural gain. Researchers have debated for years how much of the measured BMD increase reflects true bone strength versus the heavier-atom effect. Second, the fracture benefits came at the cost of serious safety problems. And third, strontium ranelate was a specific pharmaceutical compound with a particular dose and formulation; it is not the same thing as the strontium citrate or strontium carbonate supplements sold over the counter, which have never been tested in human fracture trials.
Mineralization Problems and Osteomalacia
One of the more troubling findings in strontium research involves its effect on how bone mineralizes. In animal models of kidney disease, strontium administration caused osteomalacia, a condition where bone becomes soft because the mineral component fails to deposit properly. Rats with chronic renal failure that were given strontium showed signs of impaired mineralization within two weeks. After twelve weeks, the rate at which new mineral was laid down had dropped significantly, while the layer of unmineralized bone tissue grew thicker.9PubMed. Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats Earlier work by the same research group had already established that strontium alone could drive osteomalacia in kidney-impaired rats, producing a significant increase in unmineralized bone area.10Kidney International. Strontium causes osteomalacia in chronic renal failure rats
The connection to kidney disease is important. People with reduced kidney function clear strontium from the blood much more slowly, so the element accumulates to far higher levels than it would in someone with healthy kidneys. In dialysis patients, strontium levels and strontium-to-calcium ratios in bone were elevated in those who had osteomalacia compared with other forms of bone disease.11PubMed. Strontium overload and toxicity: impact on renal osteodystrophy Animal studies showed that high strontium doses in the context of kidney failure led to a 160-fold accumulation of strontium in bone.11PubMed. Strontium overload and toxicity: impact on renal osteodystrophy Even if you have normal kidney function, this evidence raises a question: if strontium at high concentrations impairs mineralization, how confident should you be that lower concentrations are entirely benign?
Strontium and Vitamin D Interference
Another mechanism by which strontium can weaken bone involves vitamin D metabolism. Animal research has shown that dietary strontium blocks the production of calcitriol, the hormonally active form of vitamin D that the body uses to absorb calcium from the gut. In chick studies, strontium inhibited both the synthesis of this active vitamin D metabolite and intestinal calcium absorption. Supplementing with calcitriol itself could overcome the block, but the precursor form of vitamin D could not, suggesting the interference happens at a specific enzymatic step.12PubMed. Strontium induced rickets: metabolic basis
This is not just a laboratory curiosity. An epidemiological study in Turkey examined children aged six months to five years in villages with high versus low soil strontium levels. In the high-strontium villages, the prevalence of clinical rickets signs was about 32%, versus roughly 20% in low-strontium villages. The difference held even after adjusting for other factors like nutrition and sun exposure.13PubMed. Rickets and soil strontium The finding aligns with the animal evidence: strontium can disrupt vitamin D’s role in calcium handling, and growing children whose diets are grain-heavy and calcium-poor are especially vulnerable.
Cardiovascular Risks That Triggered Regulatory Action
Safety signals eventually caught up with strontium ranelate. Pooled data from randomized trials found that patients taking the drug had a higher incidence of heart attack compared with those on placebo, with roughly 1.7% versus 1.1% experiencing a non-adjudicated myocardial infarction.14PubMed Central. Cardiac concerns associated with strontium ranelate A multi-country observational study comparing strontium ranelate users with bisphosphonate users found a 25–30% excess risk of venous thromboembolism and a 35% excess risk of cardiovascular death among current strontium users.15PubMed. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance
Venous blood clots were the most frequently reported cardiovascular side effect in French pharmacovigilance data, and a severe allergic reaction called DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) was the most common serious skin reaction, appearing on average about five weeks into treatment.16PubMed. Adverse drug reactions of strontium ranelate (Protelos) in France In 2014, the European Medicines Agency’s safety committee initially recommended pulling strontium ranelate from the market entirely. The agency’s broader committee overruled that recommendation and instead restricted the drug’s use to patients with severe osteoporosis who could not take other treatments and who had no history of cardiovascular or venous thromboembolic disease.17PubMed Central. Rethinking the Appraisal and Approval of Drugs for Fracture Prevention Strontium ranelate was never approved in the United States or Canada, and production of the drug has since been discontinued.
Why Over-the-Counter Strontium Supplements Are a Different Problem
Walk through the supplement aisle or browse an online health store and you will find strontium citrate marketed for “bone support.” This is where the evidence gap becomes a chasm. There are no published human clinical trials evaluating whether strontium citrate changes fracture risk or produces genuine improvements in bone quality. There are also no data on its long-term safety.4Journal of Nutrition Health & Food Science. Change in Bone Mineral Density with Strontium Citrate: An Illusion or Reality
People who take strontium citrate and then point to their improved DEXA results as proof are falling into the measurement trap described above. The scan looks better because heavier atoms are absorbing more X-rays, not necessarily because bone structure has improved. Without fracture endpoint trials, there is no way to know whether the supplement actually reduces the risk of a broken hip or collapsed vertebra. The entire evidence base for strontium citrate supplements rests on extrapolation from strontium ranelate research, but the ranelate form was a specific pharmaceutical with a controlled dose, and even it turned out to carry risks that outweighed its benefits for most patients.
Supplement manufacturers are not required to prove efficacy before selling their products, and they can make vague “structure/function” claims without demonstrating that the supplement prevents or treats osteoporosis. This regulatory gap allows strontium citrate to remain widely available despite the absence of meaningful evidence that it helps.
The Biological Effects Are Real but Complicated
Strontium is not inert in the body. Cell studies have shown that the element can stimulate osteoblasts, the cells that build new bone, to replicate. It does this in part by activating the calcium-sensing receptor on the cell surface, essentially tricking the receptor into responding as if calcium levels were elevated.18Biochemical Pharmacology. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation On the bone-breakdown side, strontium can also trigger apoptosis in osteoclasts, the cells that dissolve old bone, through a related receptor-dependent pathway.19Journal of Biological Chemistry. The Calcium-sensing Receptor Is Involved in Strontium Ranelate-induced Osteoclast Apoptosis There are also receptor-independent effects: strontium ranelate protected osteoblasts from programmed cell death even in cells genetically engineered to lack the calcium-sensing receptor, suggesting additional survival pathways are involved.20PubMed Central. Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate
These findings often get cited by supplement advocates as proof that strontium “builds bone.” And at the cellular level, there is real activity. The problem is that positive cell-culture results do not automatically translate into clinical benefit. Plenty of substances stimulate bone cells in a dish but fail or cause harm in a living human body. With strontium, you get cellular stimulation alongside mineralization impairment, diagnostic confusion, and cardiovascular risk. The cellular mechanism is a piece of the puzzle, but it does not override the clinical and safety picture.
Who Is Most Vulnerable
Certain groups face outsized risks from strontium exposure. People with chronic kidney disease are at the top of that list, because impaired kidney function allows strontium to accumulate dramatically in bone and blood, raising the odds of osteomalacia and other mineralization defects.11PubMed. Strontium overload and toxicity: impact on renal osteodystrophy Many people in the early stages of kidney decline do not know they have it, which makes self-prescribing strontium supplements especially risky for older adults, the very population most likely to be worried about osteoporosis.
Children are also vulnerable. Growing skeletons turn over bone rapidly, creating more opportunities for strontium to incorporate into new tissue. The Turkish village study found that environmental strontium exposure was associated with significantly higher rickets rates in young children, particularly where diets were low in calcium and dairy.13PubMed. Rickets and soil strontium While children are unlikely to take bone supplements, this evidence underscores that strontium is not a benign nutrient that the body simply incorporates harmlessly.
People with existing cardiovascular disease or a history of blood clots should avoid strontium as well, given the signal for increased heart attack and venous thromboembolism risk. This was serious enough that even the restricted approval in Europe explicitly excluded patients with these conditions.
Strontium-89 in Cancer Treatment
There is one medical application of strontium that has nothing to do with building bone, and it helps illustrate the element’s affinity for the skeleton in a very different context. Strontium-89, a radioactive isotope, has been used to relieve pain from cancer that has spread to the bones. Because strontium naturally concentrates wherever bone is actively turning over, the radioactive form delivers targeted radiation to metastatic sites. In studies of prostate and breast cancer patients with painful bone metastases, strontium-89 treatment produced meaningful pain relief in roughly 80% of prostate cancer patients and about 89% of breast cancer patients, with some becoming entirely pain-free.21PubMed. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone Another evaluation found favorable pain responses in over 90% of treated patients.22PubMed Central. Strontium 89 for Palliation of Bone Metastases
The irony is instructive. Strontium’s bone-seeking behavior, the same property that supplement marketers highlight as a benefit, is harnessed in oncology precisely to damage bone tissue at metastatic sites. The element does not distinguish between helping and harming bone. It simply goes where bone is active. Whether its presence there is therapeutic or destructive depends entirely on the context, the dose, and the form.
Strontium-90 and the Nuclear Fallout Legacy
Strontium’s habit of lodging in bone tissue also made it one of the most worrying products of nuclear weapons testing during the Cold War. Strontium-90, a radioactive isotope produced by nuclear fission, enters the food chain through contaminated soil and milk, and because the body treats it like calcium, it deposits in the skeleton and teeth. The largest effort to track fallout exposure in humans collected over 300,000 baby teeth and documented a sustained rise in strontium-90 levels during the testing era, followed by a sharp decline after the 1963 atmospheric test ban treaty.23PubMed. Strontium-90 in Baby Teeth as a Basis for Estimating U.S. Cancer Deaths From Nuclear Weapons Fallout
This chapter of public health history underscores the central problem with strontium and bone. The body cannot tell strontium apart from calcium at the point of absorption and deposition. What seems like a harmless mineral substitution can, depending on the isotope and the dose, turn the skeleton into a reservoir for radiation or a scaffold that looks dense on a scan but lacks normal mineral integrity. The element’s chemical mimicry of calcium is not a feature to exploit for bone health; it is a liability the body has no good defense against.